Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to implement strategies for improved efficiency and waste reduction ("Toyota Lean") and positive deviance, a social behavioral change process, utilizing frontline healthcare personnel to reduce infection bloodstream infection and MRSA infection in outpatient dialysis care. In two outpatient dialysis units, dialysis unit healthcare staff will be educated in Toyota lean techniques and conduct periodic "discovery and action" dialogues to identify and implement care process changes to reduce infection. Outcomes to be monitored will include incidence of bloodstream infections and MRSA infections of all types. Data will be assessed at quarterly intervals using interrupted time series analysis.
| Condition | Intervention |
|---|---|
|
Blood Stream Infections MRSA Infections |
Behavioral: healthcare staff processes for infection prevention |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Testing Spread and Implementation of Novel MRSA-Reducing Practices |
- Incidence of bloodstream infections [ Time Frame: 14 months ] [ Designated as safety issue: No ]
- Incidence of MRSA infections [ Time Frame: 14 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 175 |
| Study Start Date: | July 2010 |
| Estimated Study Completion Date: | October 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
prevalent hemodialysis patients
These patients are observed in two outpatient dialysis units with a combined census of approximately 175 patients
|
Behavioral: healthcare staff processes for infection prevention
Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
|
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
prevalent hemodialysis patients at two outpatient dialysis units
Inclusion Criteria: all hemodialysis patients at two outpatient dialysis units
Exclusion Criteria:peritoneal dialysis patients
Contacts and Locations| United States, Maine | |
| Maine Medical Center | |
| Portland, Maine, United States, 04102 | |
| Principal Investigator: | Mark G Parker, MD | Maine Medical Center Research Institute |
More Information
No publications provided
| Responsible Party: | Mark G. Parker, Maine Medical Center Research Institute |
| ClinicalTrials.gov Identifier: | NCT01255943 History of Changes |
| Other Study ID Numbers: | HHSA290200600013 |
| Study First Received: | December 6, 2010 |
| Last Updated: | December 7, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Maine Medical Center Research Institute:
|
MRSA bloodstream infections hemodialysis |
Additional relevant MeSH terms:
|
Staphylococcal Infections Gram-Positive Bacterial Infections Bacterial Infections |
ClinicalTrials.gov processed this record on June 18, 2013